Quantcast
Channel: News Medical vivitrol News Feed
Browsing all 30 articles
Browse latest View live

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol...

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous...

View Article



The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of...

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet....

View Article

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug...

View Article

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and...

View Article

Positive topline results from Alkermes ALKS 9070 phase 1b study for...

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

View Article


Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress...

View Article

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on...

View Article

Generic drug gabapentin appears to be safe, effective in treating alcohol...

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a...

View Article


Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and...

View Article


Mass. to spend $20 million to combat opioid use

Governor Deval Patrick announced the plan Tuesday that will also team with five other New England states to upgrade treatment and expand coverage abuse of the drugs.

View Article

BMC opens new opioid urgent care center to treat patients with substance use...

Boston Medical Center, in collaboration with the Massachusetts Department of Public Health and the Boston Public Health Commission, has launched a new opioid urgent care center to give patients with...

View Article

People in recovery worry GOP Medicaid cuts would put treatment out of reach

Republicans in both the House and the Senate are considering big cuts to Medicaid. But those cuts endanger addiction treatment, which many people receive through the government health insurance program.

View Article

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug...

View Article


Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and...

View Article

Positive topline results from Alkermes ALKS 9070 phase 1b study for...

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

View Article


Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress...

View Article

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on...

View Article


Generic drug gabapentin appears to be safe, effective in treating alcohol...

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a...

View Article

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and...

View Article

Mass. to spend $20 million to combat opioid use

Governor Deval Patrick announced the plan Tuesday that will also team with five other New England states to upgrade treatment and expand coverage abuse of the drugs.

View Article
Browsing all 30 articles
Browse latest View live




Latest Images